Statins as effectors of key activities involved in apoE-dependent VLDL metabolism: Review and hypothesis

Vascular Pharmacology

Volumn 48, Issue 2-3, 2008, Pages 70-75

  Dergunov, Alexander D ^a   Visvikis Siest, Sophie ^b   Siest, Gerard ^a  

^a NATIONAL MEDICAL RESEARCH CENTER FOR THERAPY AND PREVENTIVE MEDICINE   (Russian Federation)

^b INSERM   (France)

Author keywords

Apolipoprotein E; Lipoprotein; Statin; Triglyceride

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CATABOLISM; CHOLESTEROL METABOLISM; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HYPOTHESIS; LIPOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; APOLIPOPROTEINS E; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPASE; LIPID METABOLISM; LIPOPROTEIN LIPASE; LIPOPROTEINS, VLDL; LIVER; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; PROTEIN CONFORMATION; RECEPTORS, LDL; TRIGLYCERIDES;

EID: 40149092788     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2007.12.001     Document Type: Review

References (75)

1. Austin M.A. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr. Atheroscler. Rep. 2 (2000) 200-207
2. Bach-Ngohou K., Ouguerram K., Frenais R., Maugere P., Ripolles-Piquer B., Zair Y., Krempf M., and Bard J.M. Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes. J. Pharmacol. Exp. Ther. 315 (2005) 363-369
3. Barbier A., Clement-Collin V., Dergunov A.D., Visvikis A., Siest G., and Aggerbeck L.P. The structure of human apolipoprotein E2, E3 and E4 in solution. 1. Tertiary and quaternary structure. Biophys. Chemist. 119 (2006) 158-169
4. Berk-Planken I.I., Hoogerbrugge N., Stolk R.P., Bootsma A.H., Jansen H., and DALI Study group. Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant. Diabetes Care 26 (2003) 427-432
5. Bey L., Maigret P., Laouenan H., and Hamilton M.T. Induction of lipoprotein lipase gene expression in 3 T3-L1 preadipocytes by atorvastatin, a cholesterol-and triglyceride-lowering drug. Pharmacology 66 (2002) 51-56
6. Bilheimer D.W., Grundy S.M., Brown M.S., and Goldstein J.L. Mevinolin and colestipol stimulate receptor-mediated clearance of low-density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl. Acad. Sci. U. S. A. 80 (1983) 4124-4128
7. Bilz S., Wagner S., Schmitz M., Bedynek A., Keller U., and Demant T. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J. Lipid Res. 45 (2004) 174-185
8. Botma G.J., van Deursen D., Vieira D., van Hoek M., Jansen H., and Verhoeven A.J.M. Sterol-regulatory-element binding protein inhibits upstream stimulatory factor-stimulated hepatic lipase gene expression. Atherosclerosis 179 (2005) 61-67
9. Briand F., Magot T., Krempf M., Nguyen P., and Ouguerram K. Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs. Eur. J. Clin. Investig. 36 (2006) 224-230
10. Busch S.J., Barnhart R.L., Martin G.A., Flanagan M.A., and Jackson R.L. Differential regulation of hepatic triglyceride lipase and 3-hydroxy-3-methylglutaryl-CoA reductase gene expression in a human hepatoma cell line, HepG2. J. Biol. Chem. 265 (1990) 22474-22479
11. Chan D.C., Watts G.F., Barrett P.H.R., Mori T.A., Beilin L.J., and Redgrave T.G. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity. J. Clin. Endocrinol. Metab. 87 (2002) 2283-2289
12. Clement-Collin V., Barbier A., Dergunov A.D., Visvikis A., Siest G., Desmadril M., Takahashi M., and Aggerbeck L.P. The structure of human apolipoprotein E2, E3 and E4 in solution. 2. Multidomain organization correlates with the stability of apoE structure. Biophys. Chem. 119 (2006) 170-185
13. Cohn J.S., Tremblay M., Batal R., Jacques H., Veilleux L., Rodriguez C., Barrett P.H.R., Dubreuil D., Roy M., Bernier L., Mamer O., and Davignon J. Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia. J. Lipid Res. 43 (2002) 1464-1471
14. De Knijff P., van den Maagdenberg A.M., Frants R.R., and Havekes L.M. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. Hum. Mutat. 4 (1994) 178-194
15. Dergunov A.D. Apolipoprotein E structure and substrate and receptor-binding activities of triglyceride-rich human plasma lipoproteins in normo- and hypertriglyceridemia. Biochemistry (Mosc.) 69 (2004) 720-737
16. Dergunov A.D., Vorotnikova Y.Y., Visvikis S., and Siest G. Homo- and hetero-complexes of exchangeable apolipoproteins in solution and in lipid-bound form. Spectrochim. Acta, Part A 59 (2003) 1127-1137
17. Dergunov A.D., Perova N.V., Visvikis S., and Siest G. Time-dependent lipid response on fluvastatin therapy of patients with hypercholesterolemia sensitive to apoE phenotype. Vasc. Pharmacol. 40 (2004) 237-245
18. Dergunov A.D., Novoselov A.V., Visvikis S., Siest G., Yakushkin V.V., and Tsibulsky V. The composition, structural properties and binding of very-low-density and low-density lipoproteins to the LDL receptor in normo- and hypertriglyceridemia: relation to the apolipoprotein E phenotype. Biol. Chem. 386 (2005) 441-452
19. Dergunov, A.D., Ponthieux, A., Mel'kin, M.V., Lambert, D., Sokolova, O.Y., Akhmedzhanov, N.M., Visvikis-Siest, S., Siest, G., unpublished results-a. Capillary isotachophoresis study of lipoprotein network sensitive to apolipoprotein E phenotype: apoE and apoC-III causal relations in lipolysis-induced triglyceride clearance in vivo.
20. Dergunov, A.D., Ponthieux, A., Mel'kin, M.V., Lambert, D., Visvikis-Siest, S., Siest, G., unpublished results-b. Capillary isotachophoresis study of lipoprotein network sensitive to apolipoprotein E phenotype: apoE distribution between lipoprotein components.
21. Desager J.P., Horsmans Y., and Harvengt C. Lecithin: cholesterol acyltransferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus low-dose colestipol. J. Clin. Pharmacol. 31 (1991) 537-542
22. Dong L.M., Wilson C., Wardell M.R., Simmons T., Mahley R.W., Weisgraber K.H., and Agard D.A. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J. Biol. Chem. 269 (1994) 22358-22365
23. Dong L.M., and Weisgraber K.H. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J. Biol. Chem. 271 (1996) 19053-19057
24. Dong L.M., Innerarity T.L., Arnold K.S., Newhouse Y.M., and Weisgraber K.H. The carboxyl terminus in apolipoprotein E2 and the seven amino acid repeat in apolipoprotein E-Leiden: role in receptor-binding activity. J. Lipid Res. 39 (1998) 1173-1180
25. Drmanac S., Heilbron D.C., Pullinger C.R., Jafari M., Gietzen D., Ukrainczyk T., Cho M.H., Frost P.H., Siradze K., Drmanac R.T., Kane J.P., and Malloy M.J. Elevated baseline triglyceride levels modulate effects of HMGCoA reductase inhibitors on plasma lipoproteins. J. Cardiovasc. Pharmacol. Ther. 6 (2001) 47-56
26. Endo K., Miyashita Y., Saiki A., Oyama T., Koide N., Ozaki H., Otsuka M., Ito Y., and Shirai K. Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia. J. Atheroscler. Thromb. 11 (2004) 341-347
27. Fiegenbaum M., Da Silveira F.R., Van Der Sand C.R., Van der Sand L.C., Ferreira M.E., Pires R.C., and Hutz M.H. Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects. Clin. Chim. Acta 362 (2005) 182-188
28. Forster L.F., Stewart G., Bedford D., Stewart J.P., Rogers E., Shepherd J., Packard C.J., and Caslake M.J. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 164 (2002) 129-145
29. Funatsu T., Suzuki K., Goto M., Arai Y., Kakuta H., Tanaka H., Yasuda S., Ida M., Nishijima S., and Miyata K. Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. Atherosclerosis 157 (2001) 107-115
30. Fusegawa Y., Tada H., Oguma T., Shiina Y., Moriguchi E.H., Tanabe T., Tamachi H., Tomoda H., and Goto Y. Effects of pravastatin on lipid transfer protein and lecithin cholesterol acyltransferase in heterozygous familial hypercholesterolemia. Tokai J. Exp. Clin. Med. 18 (1993) 81-86
31. Guerin M., Dolphin P.J., Talussot C., Gardette J., Berthezene F., and Chapman M.J. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1359-1368
32. Hime N.J., Drew K.J., Hahn C., Barter P.J., and Rye K.A. Apolipoprotein E enhances hepatic lipase-mediated hydrolysis of reconstituted high-density lipoprotein phospholipid and triacylglycerol in an isoform-dependent manner. Biochemistry 43 (2004) 12306-12314
33. Hoogerbrugge N., and Jansen H. Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia. Atherosclerosis 146 (1999) 167-174
34. Horton J.D., Shimomura I., Brown M.S., Hammer R.E., Goldstein J.L., and Shimano H. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J. Clin. Invest. 101 (1998) 2331-2339
35. Huang Y., Liu X.Q., Rall S.C., Taylor J.M., von Eckardstein A., Assmann G., and Mahley R.W. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J. Biol. Chem. 273 (1998) 26388-26393
36. Isley W.L., Miles J.M., Patterson B.W., and Harris W.S. The effect of high-dose simvastatin on triglyceride-rich lipoprotein metabolism in patients with type 2 diabetes mellitus. J. Lipid Res. 47 (2006) 193-200
37. Jansen H., Verhoeven A.J.M., and Sijbrands E.J.G. Hepatic lipase: a pro- or anti-atherogenic protein?. J. Lipid Res. 43 (2002) 1352-1362
38. Kassai A., Illyes L., Mirdamadi H.Z., Seres I., Kalmar T., Audikovszky M., and Paragh G. The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin. Biochem. 40 (2007) 1-5
39. Kobayashi J., Maruyama T., Masuda M., and Shinomiya M. Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects. Clin. Chim. Acta 314 (2001) 261-264
40. Korhonen T., Hannuksela M.L., Seppanen S., Kervinen K., Kesaniemi Y.A., and Savolainen M.J. The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein AI levels in hypercholesterolaemic patients on colestipol and lovastatin treatment. Eur. J. Clin. Pharmacol. 54 (1999) 903-910
41. Le N.A., Innis-Whitehouse W., Li X., Bakker-Arkema R., Black D., and Brown W.V. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism 49 (2000) 167-177
42. Mahley R.W., Huang Y., and Weisgraber K.H. Putting cholesterol in its place: apoE and reverse cholesterol transport. J. Clin. Invest. 116 (2006) 1226-1229
43. Maitland-van der Zee A.H., Jukema J.W., Zwinderman A.H., Hallman D.M., De Boer A., Kastelein J.J., and De Knijff P. Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). Acta Cardiol. 61 (2006) 327-331
44. *3. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 91-97
45. Matsuura F., Wang N., Chen W., Jiang X.C., and Tall A.R. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE-and ABCG1-dependent pathway. J. Clin. Invest. 116 (2006) 1435-1442
46. Mensenkamp A.R., Jong M.C., van Goor H., van Luyn M.J.A., Bloks V., Havinga R., Voshol P.J., Hofker M.H., van Dijk K.W., Havekes L.M., and Kuipers F. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. J. Biol. Chem. 274 (1999) 35711-35718
47. Murdoch S.J., and Breckenridge W.C. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL. Atherosclerosis 118 (1995) 193-212
48. Napoli C., Leccese M., Palumbo G., de Nigris F., Chiariello P., Zuliani P., Somma P., Di Loreto M., De Matteis C., Cacciatore F., Abete P., Liguori A., Chiariello M., and D'Armiento F.P. Effects of vitamin E and HMG-CoA reductase inhibition on cholesteryl ester transfer protein and lecithin-cholesterol acyltransferase in hypercholesterolemia. Coron. Artery Dis. 9 (1998) 257-264
49. Ordovas J.M., Cupples L.A., Corella D., Otvos J.D., Osgood D., Martinez A., Lahoz C., Coltell O., Wilson P.W., and Schaefer E.J. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framigham study. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1323-1329
50. Ouguerram K., Magot T., Zair Y., Marchini J.S., Charbonnel B., Laouenan H., and Krempf M. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes. J. Pharmacol. Exp. Ther. 306 (2003) 332-337
51. Pedro-Botet J., Schaefer E.J., Bakker-Arkema R.G., Black D.M., Stein E.M., Corella D., and Ordovas J.M. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 158 (2001) 183-193
52. Rashid S., Uffelman K.D., Barrett P.H.R., and Lewis G.F. Effect of atorvastatin on high-density lipoprotein apolipoprotein A-I production and clearance in the New Zealand white rabbit. Circulation 106 (2002) 2955-2960
53. Raussens V., Slupsky C.M., Sykes B.D., and Ryan R.O. Lipid-bound structure of an apolipoprotein E-derived peptide. J. Biol. Chem. 278 (2003) 25998-26006
54. Roglans N., Sanguino E., Peris C., Alegret M., Vazquez M., Adzet T., Diaz C., Hernandez G., Laguna J.C., and Sanchez R.M. Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J. Pharmacol. Exp. Ther. 302 (2002) 232-239
55. Roglans N., Verd J.C., Peris C., Alegret M., Vazquez M., Adzet T., Diaz C., Hernandez G., Laguna J.C., and Sanchez R.M. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production. Lipids 37 (2002) 445-454
56. Rye K.A., Bright R., Psaltis M., and Barter P.J. Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E. J. Lipid Res. 47 (2006) 1025-1036
57. Saiki A., Murano T., Watanabe F., Oyama T., Miyashita Y., and Shirai K. Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J. Atheroscler. Thromb. 12 (2005) 163-168
58. Saito H., Dhanasekaran P., Baldwin F., Weisgraber K.H., Lund-Katz S., and Phillips M.C. Lipid binding-induced conformational change in human apolipoprotein E. Evidence for two lipid-bound states on spherical particles. J. Biol. Chem. 276 (2001) 40949-40954
59. Saku K., Sasaki J., and Arakawa K. Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia. Clin. Ther. 11 (1989) 247-257
60. Schaefer E.J., McNamara J.R., Tayler T., Daly J.A., Gleason J.A., Seman L.J., Ferrari A., and Rubenstein J.J. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am. J. Cardiol. 90 (2002) 689-696
61. Scharnagl H., Schinker R., Gierens H., Nauck M., Wieland H., and Marz W. Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem. Pharmacol. 62 (2001) 1545-1555
62. Schneider J.G., von Eynatten M., Parhofer K.G., Volkmer J.E., Schiekofer S., Hamann A., Nawroth P.P., and Dugi K.A. Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Atherosclerosis 175 (2004) 325-331
63. Schoonjans K., Peinado-Onsurbe J., Fruchart J.C., Tailleux A., Fivet C., and Auwerx J. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett. 452 (1999) 160-164
64. Segall M.L., Dhanasekaran P., Baldwin F., Anantharamaiah G.M., Weisgraber K.H., Phillips M.C., and Lund-Katz S. Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization. J. Lipid Res. 43 (2002) 1688-1700
65. Sorli J.V., Corella D., Frances F., Ramirez J.B., Gonzalez J.I., Guillen M., and Portoles O. The effect of the APOE polymorphism on HDL-C concentrations depends on the cholesterol ester transfer protein gene variation in a Southern European population. Clin. Chim. Acta 366 (2006) 196-203
66. Stein E.A., Lane M., and Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am. J. Cardiol. 81 (1998) 66B-69B
67. Utermann G., Jaeschke M., and Menzel J. Familial hyperlipoproteinemia type III: deficiency of a specific apolipoprotein (apo E-III) in the very-low-density lipoproteins. FEBS Lett. 56 (1975) 352-355
68. Verd J.C., Peris C., Alegret M., Diaz C., Hernandez G., Vazquez M., Adzet T., Laguna J.C., and Sanchez R.M. Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits. Br. J. Pharmacol. 127 (1999) 1479-1485
69. Watts G.F., Naoumova R.P., Kelly J.M., Riches F.M., Croft K.D., and Thompson G.R. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects. Am. J. Physiol. 273 (1997) E462-E470
70. Watts G.F., Barrett P.H.R., Ji J., Serone A.P., Chan D.C., Croft K.D., Loehrer F., and Johnson A.G. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 52 (2003) 803-811
71. Weisgraber K.H. Apolipoprotein E: structure-function relationships. Adv. Protein Chem. 45 (1994) 249-302
72. Wilson C., Wardell M.R., Weisgraber K.H., Mahley R.W., and Agard D.A. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252 (1991) 1817-1822
73. Zambon A., Hokanson J.E., Brown B.G., and Brunzell J.D. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 99 (1999) 1959-1964
74. Zambon A., Deeb S.S., Brown B.G., Hokanson J.E., and Brunzell J.D. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation 103 (2001) 792-798
75. Zhao S.P., Smelt A.H., Van den Maagdenberg A.M., Van Tol A., Vroom T.F., Gevers Leuven J.A., Frants R.R., Havekes L.M., Van der Laarse A., and Van 't Hooft F.M. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158->Cys), E3-Leiden, and E2(Lys146->Gln), and effects of treatment with simvastatin. Arterioscler.Thromb. 14 (1994) 1705-1716